- Current report filing (8-K)
September 30 2010 - 4:51PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): September 28, 2010
K-V PHARMACEUTICAL COMPANY
(Exact name of registrant as specified in its charter)
Commission File Number 1-9601
|
|
|
|
|
Delaware
|
|
1-9601
|
|
43-0618919
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
One Corporate Woods Drive Bridgeton, MO
|
|
63044
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(314)
645-6600
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act.
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
|
Item 1.01.
|
Entry into a Material Definitive Agreement.
|
As previously reported in the Current Report on Form 8-K filed September 17, 2010 by K-V Pharmaceutical Company (the Registrant), on
September 13, 2010, the Registrant entered into a loan agreement with U.S. Healthcare I, L.L.C. and U.S. Healthcare II, L.L.C. for a $20 million loan secured by assets of the Registrant. The loan agreement included a period of exclusivity
through September 28, 2010 to negotiate an expanded, longer-term financial arrangement among the Registrant and U.S. Healthcare I, L.L.C. and U.S. Healthcare II, L.L.C.
On September 28, 2010, at the request of U.S. Healthcare I, L.L.C. and U.S. Healthcare II, L.L.C., the Registrant agreed to extend the exclusivity
period through October 4, 2010.
The Registrant will post this Form 8-K on its Internet website at www.kvpharmaceutical.com. References
to the Registrants website address are included in this Form 8-K only as inactive textual references and the Registrant does not intend them to be active links to its website. Information contained on the Registrants website does not
constitute part of this Form 8-K.
* * *
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: September 30, 2010
|
|
|
K-V PHARMACEUTICAL COMPANY
|
|
|
By:
|
|
/
S
/ G
REGORY
J. D
IVIS
,
J
R
.
|
|
|
Gregory J. Divis, Jr.
|
|
|
Interim President and Interim Chief Executive Officer
|
K V Pharma (NYSE:KV.A)
Historical Stock Chart
From May 2024 to Jun 2024
K V Pharma (NYSE:KV.A)
Historical Stock Chart
From Jun 2023 to Jun 2024